Oxypurinol alkali and alkaline earth salts in amorphorous or crystalline form as agents for treating hyperuricaemia and gout
US5661154A · kind A · utility
1Cited by
3References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 6, 1995 |
| Grant date | Aug 26, 1997 |
| Priority date | — |
| Expiry date | Feb 6, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/519
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Treatment of hyperuricaemia and gout is possible by agents, among usual carriers and adjuvants containing pharmakologically active doses of oxypurinol alkali and/or alkaline earth salts in amorphous or crystalline form.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.